A Phase 4 interventional study of Trospium Chloride in Elderly, Pharmacokinetics and Overactive Bladder, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 65 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-26.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Urinary Bladder, Overactive by AbbVie — none open to participants now, none under way, none of them phase 3. Urinary Bladder, Overactive · AbbVie.
Among the 28 studies in Urinary Bladder, Overactive by AbbVie, this one is the 22nd largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2009, is one of 9 in phase 4, and was the 9th registered.
859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.
Browse Urinary Bladder, Overactive studies →None of the 28 studies in Urinary Bladder, Overactive by AbbVie is open now. The open studies under Urinary Bladder, Overactive, anywhere →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 65 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 70 across 650 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 265 across the 22 interventional studies, 447 across the 6 observational. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Urinary Bladder, Overactive by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Trospium Chloride Extended Release, 60 mg
Drug: Trospium Chloride
Extended release, 60 mg, oral daily
Also known as: Sanctura XR™ 60 mg
Cerebral Spinal Fluid Levels of Trospium at Day 10, Hour 5
Cerebral spinal fluid levels of Trospium at day 10, hour 5. Cerebral spinal fluid was collected from each patient.
Time frame: Day 10, Hour 5
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose
The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory).
Time frame: Day 10
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Delayed Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose
The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The delayed recall score provides a measure of the patient's recent memory. The total score ranges from 0 (no memory) to 12 (best memory).
Time frame: Day 10
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Total Score at Day 10 Post-Dose
The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). Due to technical problems associated with the administration of the test, the results were invalid.
Time frame: Day 10
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall Score at Day 10 Post-Dose
The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and a yes/no delayed recognition trial. The delayed recall score, derived from the delayed recall trial, provides a measure of the patient's recent memory. The total score ranges from 0 (no memory) to 12 (best memory). Due to technical problems associated with the administration of the test, the results were invalid.
Time frame: Day 10
| Milestone | Trospium Chloride Extended Release, 60 mg |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
Cerebral spinal fluid levels of Trospium at day 10, hour 5. Cerebral spinal fluid was collected from each patient.
| Picograms per milliliter (pg/mL) | Trospium Chloride Extended Release, 60 mg |
|---|---|
| Cerebral Spinal Fluid Levels of Trospium at Day 10, Hour 5 | NA ± NA |
The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory).
| Percentage of Subjects | Trospium Chloride Extended Release, 60 mg |
|---|---|
| Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose | 100 |
The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The delayed recall score provides a measure of the patient's recent memory. The total score ranges from 0 (no memory) to 12 (best memory).
| Percentage of Subjects | Trospium Chloride Extended Release, 60 mg |
|---|---|
| Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Delayed Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose | 91.7 |
The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). Due to technical problems associated with the administration of the test, the results were invalid.
| Percentage of Subjects | Trospium Chloride Extended Release, 60 mg |
|---|---|
| Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Total Score at Day 10 Post-Dose | NA |
The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and a yes/no delayed recognition trial. The delayed recall score, derived from the delayed recall trial, provides a measure of the patient's recent memory. The total score ranges from 0 (no memory) to 12 (best memory). Due to technical problems associated with the administration of the test, the results were invalid.
| Percentage of Subjects | Trospium Chloride Extended Release, 60 mg |
|---|---|
| Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall Score at Day 10 Post-Dose | NA |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trospium Chloride Extended Release, 60 mg | — | 0/12 (0%) | 10/12 (83.3%) |
| Event | Trospium Chloride Extended Release, 60 mg |
|---|---|
| HeadacheNervous system disorders | 7/12 |
| NauseaGastrointestinal disorders | 3/12 |
| VomitingGastrointestinal disorders | 3/12 |
| ConstipationGastrointestinal disorders | 2/12 |
| Dry MouthGastrointestinal disorders | 2/12 |
| FlatulenceGastrointestinal disorders | 2/12 |
| Low back painMusculoskeletal and connective tissue disorders | 2/12 |
| FolliculitisSkin and subcutaneous tissue disorders | 1/12 |
| Change in tasteGeneral disorders | 1/12 |
| Increased appetiteMetabolism and nutrition disorders | 1/12 |
| Age, Continuous(years) | Trospium Chloride Extended Release, 60 mg |
|---|---|
| Median | 68 (65 to 74) |
| Sex: Female, Male(Participants) | Trospium Chloride Extended Release, 60 mg |
|---|---|
| Female | 7 |
| Male | 5 |
The record gives a start of Apr 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trospium chloride